| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 3453 | 2011 |
| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R de Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 3138 | 2012 |
| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 2044 | 2013 |
| A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma F Saad, DM Gleason, R Murray, S Tchekmedyian, P Venner, L Lacombe, ... Journal of the National Cancer Institute 94 (19), 1458-1468, 2002 | 1785 | 2002 |
| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 1735 | 2014 |
| Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer F Saad, DM Gleason, R Murray, S Tchekmedyian, P Venner, L Lacombe, ... Journal of the National Cancer Institute 96 (11), 879-882, 2004 | 1238 | 2004 |
| Denosumab in men receiving androgen-deprivation therapy for prostate cancer MR Smith, B Egerdie, NH Toriz, R Feldman, TLJ Tammela, F Saad, ... New England Journal of Medicine 361 (8), 745-755, 2009 | 1078 | 2009 |
| Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo … K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ... The lancet oncology 13 (10), 983-992, 2012 | 1077 | 2012 |
| The molecular taxonomy of primary prostate cancer A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ... Cell 163 (4), 1011-1025, 2015 | 927 | 2015 |
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall … CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ... The Lancet Oncology 16 (2), 152-160, 2015 | 744 | 2015 |
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial MR Smith, F Saad, R Coleman, N Shore, K Fizazi, B Tombal, K Miller, ... The Lancet 379 (9810), 39-46, 2012 | 731 | 2012 |
| Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors JE Brown, RJ Cook, P Major, A Lipton, F Saad, M Smith, KA Lee, M Zheng, ... Journal of the National Cancer Institute 97 (1), 59-69, 2005 | 578 | 2005 |
| Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid RE Coleman, P Major, A Lipton, JE Brown, KA Lee, M Smith, F Saad, ... Journal of Clinical Oncology 23 (22), 4925-4935, 2005 | 570 | 2005 |
| Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases F Saad, JE Brown, C Van Poznak, T Ibrahim, SM Stemmer, AT Stopeck, ... Annals of oncology 23 (5), 1341-1347, 2011 | 516 | 2011 |
| Pathologic fractures correlate with reduced survival in patients with malignant bone disease F Saad, A Lipton, R Cook, YM Chen, M Smith, R Coleman Cancer 110 (8), 1860-1867, 2007 | 510 | 2007 |
| Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel M Aapro, PA Abrahamsson, JJ Body, RE Coleman, R Colomer, L Costa, ... Annals of oncology 19 (3), 420-432, 2007 | 510 | 2007 |
| Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials A Lipton, K Fizazi, AT Stopeck, DH Henry, JE Brown, DA Yardley, ... European Journal of Cancer 48 (16), 3082-3092, 2012 | 408 | 2012 |
| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 380 | 2018 |
| eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression L Furic, L Rong, O Larsson, IH Koumakpayi, K Yoshida, A Brueschke, ... Proceedings of the National Academy of Sciences 107 (32), 14134-14139, 2010 | 379 | 2010 |
| Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer MR Smith, F Kabbinavar, F Saad, A Hussain, MC Gittelman, DL Bilhartz, ... Journal of Clinical Oncology 23 (13), 2918-2925, 2005 | 378 | 2005 |
Kim N. ChiProfessor of Medicine, University of British ColumbiaVerified email at bccancer.bc.ca
